Research + datasets we verified ourselves.
Original research and primary-source compilations from GLPZoom Editorial. Free to use under Creative Commons Attribution 4.0 — cite us if it helps you.
For journalists
Need a stat on deadline?
Email press@glpzoom.com — same-day response on deadline requests before noon ET.
press@glpzoom.comPublished datasets
1 datasetGLP-1 Manufacturer Direct-Pay Programs: 2026 Pricing Snapshot
Publicly-disclosed pricing, eligibility, and access terms for 5 FDA-approved manufacturer direct-pay programs: NovoCare (Wegovy), LillyDirect (Zepbound), savings cards, and patient-assistance programs.
Published 2026-06-02
Editorial integrity
What you can rely on when you cite our data.
Verified directly, not aggregated
Every record carries a verified_on date — the day we confirmed the data on the original source. No aggregate-from-Healthline shortcuts.
Sources linked inline
We don't paraphrase or compress source information into summary numbers. Source URLs are part of every record.
Change-logged
When pricing, eligibility, or program terms change, we update the dataset and log the change. Historical snapshots remain available.
Free to reuse, with attribution
Datasets are published under Creative Commons Attribution 4.0. Journalists, researchers, and content publishers can cite freely.
In development
Datasets we're verifying for upcoming release.
- State-by-state telehealth GLP-1 prescribing legalitymid-2026
- Insurance-carrier prior-authorization approval-timeline benchmarkQ3 2026
- Compounded GLP-1 pricing snapshot across 503A pharmaciesQ3 2026
See also our methodology and editorial policy.